Emergent BioSolutions Announces Presentation on Bispecific Protein Therapeutic at 24th Annual EORTC-NCI-AACR Symposium
Emergent BioSolutions Inc. announced today that an abstract on its bispecific protein therapeutic targeting prostate cancer has been accepted for presentation at the 24th Annual EORTC-NCI-AACR...
Emergent BioSolutions Announces Acceptance of TRU-016 and Bispecific Abstracts for Presentation at 2012 American Society of Hematology Annual Meeting
Emergent BioSolutions Inc. announced today that three abstracts on its humanized anti-CD37 mono-specific protein therapeutic, TRU-016, and bispecific protein therapeutics have been accepted for...
Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2012
Total revenues for Q3 and the first nine months of 2012 were $66.6 million and $187.3 million, respectively. Net income for Q3 2012 was $6.6 million, or $0.18 per basic share. Net income for the...
Emergent BioSolutions Announces Growth Plan Through 2015
Emergent BioSolutions Inc. (NYSE: EBS) announced today a growth plan designed to advance the company’s leadership position in the biodefense field and expand its product offerings in specialty...
Emergent BioSolutions Initiates Phase 1b Study of TRU-016 in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Emergent BioSolutions Inc. (NYSE: EBS) announced today the initiation of a Phase 1b study (Protocol 16009) of TRU-016 in combination with rituximab for patients with previously untreated chronic...
Emergent BioSolutions to Release Third Quarter 2012 Financial Results and Conduct a Conference Call on November 1, 2012
Emergent BioSolutions Inc. announced today that it will report financial results for the third quarter 2012 on Thursday, November 1, 2012, before market open. Company management will host a...
BARDA Exercises Contract Option as Emergent BioSolutions Achieves Significant Progress in rPA Anthrax Vaccine Development
Emergent BioSolutions announced today that, after completion of an inter-agency In Process Review, the Biomedical Advanced Research Development Authority (BARDA) of the U.S. Department of Health and...
Emergent BioSolutions to Present at ThinkEquity’s 9th Annual Growth Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the ThinkEquity 9th Annual Growth Conference in New York on Wednesday, September 12,...
Emergent BioSolutions to Present at Wedbush 2012 Life Sciences Management Access Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Wedbush 2012 Life Sciences Management Access Conference in New York on Tuesday,...
Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2012
Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the second quarter and six months ended June 30, 2012. Total revenues for Q2 and the first six months of 2012 were...
Emergent BioSolutions to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 2, 2012
Company management will host a conference call at 5:00 pm Eastern on August 2, 2012 to discuss the financial results for the second quarter of 2012, recent business developments, revenue guidance for...
BARDA and Emergent BioSolutions Partner to Establish Center for Innovation in Advanced Development and Manufacturing
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into a public-private partnership with the Biomedical Advanced Research and Development Authority (BARDA), within the Office...